anti-inflammatory therapies - versus standard of care - for COVID 19 outpatients pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.42 [0.01, 12.75]< 10%1 study (1/-)68.7 %NAnot evaluable crucial-
deaths 0.42 [0.01, 12.75]< 10%1 study (1/-)68.7 %NAnot evaluable crucial-
hospitalization or death 1.29 [0.36, 4.67]< 10%1 study (1/-)34.9 %NAnot evaluable crucial-
hospitalization 1.73 [0.43, 7.07]< 10%1 study (1/-)22.2 %NAnot evaluable important-
recovery 0.92 [0.72, 1.17]> 10%1 study (1/-)24.7 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.